4//SEC Filing
Session R.A. II 4
Accession 0001209191-22-013156
CIK 0001806310other
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 4:17 PM ET
Size
5.6 KB
Accession
0001209191-22-013156
Insider Transaction Report
Form 4
Session R.A. II
DirectorPresident and CEO10% Owner
Transactions
- Award
Employee Stock Option (right to buy)
2022-02-23+217,850→ 217,850 totalExercise: $5.96Exp: 2032-02-23→ Common Stock (217,850 underlying)
Footnotes (1)
- [F1]25% of the total number of shares underlying the option shall vest and become exercisable on February 23, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Documents
Issuer
Taysha Gene Therapies, Inc.
CIK 0001806310
Entity typeother
Related Parties
1- filerCIK 0001701846
Filing Metadata
- Form type
- 4
- Filed
- Feb 24, 7:00 PM ET
- Accepted
- Feb 25, 4:17 PM ET
- Size
- 5.6 KB